A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF ALZHEIMER'S DISEASE (AD)
Principal Investigator(s)
Royall, Donald R
Funded by
NOVARTIS PHARMACEUTICALS CORPORATION
Research Start Date
Status
Active